EPISODE · Feb 26, 2021 · 31 MIN
Special Populations and Immune Checkpoint Inhibitors: Are They Safe?
from Keeping Current CME
In this activity, three experts discuss how to incorporate immune checkpoint inhibitor therapy into the management of individuals classified as part of the "special population" of patients not generally included in clinical trials. Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/946383?src=mkm_podcast_addon_946383
Embed this episode
NOW PLAYING
Special Populations and Immune Checkpoint Inhibitors: Are They Safe?
0:00
31:26
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of Keeping Current CME?
This episode is 31 minutes long.
When was this Keeping Current CME episode published?
This episode was published on February 26, 2021.
Can I download this Keeping Current CME episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!